Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Secale cereale pollen is an extract derived from the pollen of rye grass. It is utilized in two distinct therapeutic areas: allergy/immunology and urology. In the context of allergy, it is used as an allergen-specific immunotherapy (AIT) agent to treat seasonal allergic rhinitis and rhinoconjunctivitis. It works by inducing immune tolerance, characterized by the induction of regulatory T-cells and the production of allergen-specific IgG4 antibodies that block IgE-mediated responses. In urology, a standardized formulation (often known as Cernilton or cernitin) is used as a botanical treatment for benign prostatic hyperplasia (BPH) and chronic prostatitis. Its urological mechanism of action involves anti-inflammatory effects, relaxation of urethral smooth muscle, and potential modulation of testosterone metabolism within the prostate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on secale cereale pollen.